what are the risks of tirzepatide promise tirzepatide: A narrative review of metabolic benefits Long-Term Safety of Tirzepatide: What
Description
04, 2025 (GLOBE NEWSWIRE) -- Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, today announced the launch of the Noom Microdose GLP-1Rx Program, a groundbreaking offering designed to unlock weight loss and long-term health benefits while minimizing side effects through personalized microdoses of GLP-1 medication, when clinically appropriate
Since weight loss is still considered a lifestyle choice rather than a medical necessity, many insurance companies wont cover it unless its prescribed to manage a chronic health condition like type 2 diabetes
It is the GLP-1 medication most people are familiar with, but liraglutide offers a well-established alternative
Appetite suppression and weight loss are separate processes
and a potential reduction in the risk of developing type 2 diabetes or cardiovascular disease
Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes
